About Sihuan
HKEx stock code 00460.HK
A fast growing large pharmaceutical company
HKEx stock code 00460.HK
In 2001, Hainan Sihuan Pharmaceutical Co., Ltd. was founded, marking the starting point of the entrepreneurial development of Sihuan Pharmaceutical Holdings Group. At its start stage, Sihuan Pharmaceutical attached great importance to marketing. Later, with the establishment of Hainan Sihuan Cardio-Cerebral Vascular Drug Research Institute, it is able to make progress both in market development and new product R&D, thus facilitating the company to develop rapidly.
Sihuan Pharmaceutical Holdings Group was incorporated in Bermuda in April 2006, and was successfully listed in Singapore in March 2007. In 2009, in order to meet the needs of greater development, Sihuan Pharmaceutical Holdings Group completed privatization and was delisted from Singapore, and was successfully re-listed in Hong Kong in 2010.
Up to now, Sihuan Pharmaceutical Holdings Group has developed into a pharmaceutical enterprise with strong R&D capabilities, high-quality product structure, and sound production management system. Together with a unique marketing model and professional services, it deeply engages in the cardio-cerebral vascular drug industry in China to serve human health.
Strong R&D capabilities
Innovative R&D is the core competence of Sihuan Pharmaceutical. It invests more than 10% of its annual sales revenue to improve R&D and to build a new product R&D system that is in line with international standards and conduct cooperation on global projects.
Under the leadership of senior scientists at Sihuan Drug Research Institute, more than 600 outstanding R&D personnel at home and abroad are committed to the R&D of innovative patented drugs and first-to-market generic drugs. At present, there are more than 150 new drugs under development, including 19 innovative patented drugs; more than 700 patent applications have been filed, and more than 300 patents have been granted, including more than 50 international patents.
Diversified product portfolio, unique and successful marketing model
Sihuan Pharmaceutical’s strong marketing system and unique marketing model ensure its dominant position in the industry. According to 2018 IMS Health data, Sihuan Pharmaceutical continued to be one of the largest pharmaceutical company in China’s prescription drug market in terms of hospital purchase with a market share of 8.3% in the cardio-cerebral vascular prescription drug market in China.
Sihuan Pharmaceutical has a multi-dimensional sales network nationwide with more than 3,000 distributors and 600 sales & product managers, enabling Sihuan Pharmaceutical’s products to cover the whole country.
It holds more than 20,000 innovative academic promotion activities in a year. There are nearly 70,000 doctor members registered at Sihuan Online Medical Academy.
Strict product quality management and control system
Product quality is critical to the survival and development of Sihuan Pharmaceutical. It has introduced European production design and management system and adopted high-standard preparation process. The production lines of API, large- and small-volume injection, freeze-dried powder injection, tablet, capsule, and granule owned by Sihuan Pharmaceutical’s production sites have all obtained Chinese new GMP certification and passed U.S. FDA on-site inspection.
Strict quality audit and evaluation improves qualification rate in ex-factory and regulatory inspection and fully ensures drug efficacy and safety.
